Safety of Radiation with Modern Breast Cancer Drugs
Part of Cancer, Skin clinical trials.
This study checks if giving certain modern breast cancer drugs at the same time as radiation is safe. It's for women who need radiation and are also taking one of these drugs: capecitabine, a CDK4/6 inhibitor, a PARP inhibitor, immunotherapy, or a HER2 inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with breast cancer (and are female).
- Your doctor has recommended radiation therapy to your chest, breast, or nearby lymph nodes.
- You are also planning to take one of these medicines with your radiation: capecitabine, a CDK4/6 inhibitor, a PARP inhibitor, immunotherapy (ICI), or a HER2 inhibitor.
- You have not had an allergic reaction to any of these medicines before.
- You are not planning to receive only trastuzumab (Herceptin) during or after radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways of giving radiation to lymph node areas near the collarbone after surgery for invasive breast cancer. It aims to see which radiation approach works better and is safer for preventing cancer returning in these lymph nodes.
This trial is testing the safety and effectiveness of combining radiation therapy with newer cancer medications (like targeted therapy or immunotherapy) for people whose breast cancer has spread to other parts of the body (stage IV). The goal is to see if adding radiation can help control the cancer better.
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
This trial tests giving chemotherapy, an immunotherapy drug (PD-1 inhibitor), and different types of radiation before surgery for people with a common type of breast cancer (HR+/HER2-). The goal is to see which radiation plan works best to shrink tumors.
This trial tests a shorter, more intense course of radiation to the whole breast after chemotherapy in women age 60 or older with early-stage breast cancer. It is designed for those who had a lumpectomy and are at higher risk based on genetic tests like Mammaprint or Oncotype.
This trial compares a shorter, more concentrated radiation schedule versus a standard shorter schedule after breast-conserving surgery. It looks at whether the treatment works well and is safe, especially for women whose lymph nodes also need radiation.
Hear when a new Radiotherapy; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.